Stereotactic Body Radiotherapy for Oligometastatic Renal Cell Carcinoma-are We Ready to Roll?

Overview

Journal Ann Transl Med

Publisher AME Publishing Company

Date 2019 Oct 29

PMID 31656759

Citations 1

Authors

Christian C Okoye

Ravi B Patel

Shankar Siva

Alexander V Louie

Simon S Lo

Affiliations

Soon will be listed here.

Citing Articles

Metastasis-directed stereotactic body radiotherapy for oligometastatic renal cell carcinoma: extent of tumor burden eradicated by radiotherapy.

Liu Y, Long W, Zhang Z, Zhang Z, Mai L, Huang S World J Urol. 2021; 39(11):4183-4190.

PMID: 34043023 PMC: 8571216. DOI: 10.1007/s00345-021-03742-1.

References

De Meerleer G, Khoo V, Escudier B, Joniau S, Bossi A, Ost P . Radiotherapy for renal-cell carcinoma. Lancet Oncol. 2014; 15(4):e170-7. DOI: 10.1016/S1470-2045(13)70569-2. View

Alt A, Boorjian S, Lohse C, Costello B, Leibovich B, Blute M . Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer. 2011; 117(13):2873-82. DOI: 10.1002/cncr.25836. View

Baird J, Monjazeb A, Shah O, McGee H, Murphy W, Crittenden M . Stimulating Innate Immunity to Enhance Radiation Therapy-Induced Tumor Control. Int J Radiat Oncol Biol Phys. 2017; 99(2):362-373. PMC: 5604475. DOI: 10.1016/j.ijrobp.2017.04.014. View

Franzese C, Franceschini D, Di Brina L, DAgostino G, Navarria P, Comito T . Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell Carcinoma. J Urol. 2018; 201(1):70-75. DOI: 10.1016/j.juro.2018.08.049. View

Kroeze S, Fritz C, Hoyer M, Lo S, Ricardi U, Sahgal A . Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review. Cancer Treat Rev. 2017; 53:25-37. DOI: 10.1016/j.ctrv.2016.11.013. View

De Wolf K, Rottey S, Vermaelen K, Decaestecker K, Sundahl N, De Lobel L . Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial. Radiat Oncol. 2017; 12(1):157. PMC: 5610443. DOI: 10.1186/s13014-017-0893-x. View

Luke J, Lemons J, Karrison T, Pitroda S, Melotek J, Zha Y . Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018; 36(16):1611-1618. PMC: 5978468. DOI: 10.1200/JCO.2017.76.2229. View

Amini A, Altoos B, Bourlon M, Bedrick E, Bhatia S, Kessler E . Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant?. Pract Radiat Oncol. 2015; 5(6):e589-e596. PMC: 4706456. DOI: 10.1016/j.prro.2015.05.004. View

Heng D, Xie W, Regan M, Harshman L, Bjarnason G, Vaishampayan U . External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013; 14(2):141-8. PMC: 4144042. DOI: 10.1016/S1470-2045(12)70559-4. View

10.

Widder J, Klinkenberg T, Ubbels J, Wiegman E, Groen H, Langendijk J . Pulmonary oligometastases: metastasectomy or stereotactic ablative radiotherapy?. Radiother Oncol. 2013; 107(3):409-13. DOI: 10.1016/j.radonc.2013.05.024. View

11.

Brooks E, Chang J . Time to abandon single-site irradiation for inducing abscopal effects. Nat Rev Clin Oncol. 2018; 16(2):123-135. DOI: 10.1038/s41571-018-0119-7. View

12.

Flanigan R, Campbell S, Clark J, Picken M . Metastatic renal cell carcinoma. Curr Treat Options Oncol. 2003; 4(5):385-90. DOI: 10.1007/s11864-003-0039-2. View

13.

Meyer C, Sun M, Karam J, Leow J, de Velasco G, Pal S . Complications After Metastasectomy for Renal Cell Carcinoma-A Population-based Assessment. Eur Urol. 2017; 72(2):171-174. DOI: 10.1016/j.eururo.2017.03.005. View

14.

Zaid H, Parker W, Safdar N, Gershman B, Erwin P, Murad M . Outcomes Following Complete Surgical Metastasectomy for Patients with Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. J Urol. 2016; 197(1):44-49. DOI: 10.1016/j.juro.2016.07.079. View

15.

Dagan R, Lo S, Redmond K, Poon I, Foote M, Lohr F . A multi-national report on stereotactic body radiotherapy for oligometastases: Patient selection and follow-up. Acta Oncol. 2016; 55(5):633-7. DOI: 10.3109/0284186X.2015.1118659. View

16.

Potters L, Kavanagh B, Galvin J, Hevezi J, Janjan N, Larson D . American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2010; 76(2):326-32. DOI: 10.1016/j.ijrobp.2009.09.042. View

17.

Stenman M, Sinclair G, Paavola P, Wersall P, Harmenberg U, Lindskog M . Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005-2014. Radiother Oncol. 2018; 127(3):501-506. DOI: 10.1016/j.radonc.2018.04.028. View

18.

Motzer R, Tannir N, Mcdermott D, Frontera O, Melichar B, Choueiri T . Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018; 378(14):1277-1290. PMC: 5972549. DOI: 10.1056/NEJMoa1712126. View

19.

Morris Z, Guy E, Werner L, Carlson P, Heinze C, Kler J . Tumor-Specific Inhibition of Vaccination by Distant Untreated Tumor Sites. Cancer Immunol Res. 2018; 6(7):825-834. PMC: 6030484. DOI: 10.1158/2326-6066.CIR-17-0353. View

20.

Young K, Baird J, Savage T, Cottam B, Friedman D, Bambina S . Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy. PLoS One. 2016; 11(6):e0157164. PMC: 4900555. DOI: 10.1371/journal.pone.0157164. View